Skip to main content

Table 5 Risk factors for treatment failure in pediatric invasive candidiasis by univariate and multivariate analysis

From: Comparison of the incidence, clinical features and outcomes of invasive candidiasis in children and neonates

Risk factors

Univariate analysis

Multivariate analysis

Treatment success (total n = 261)

Treatment failure (total n = 81)

P value

Adjusted OR (95% CI)

P value

Neonates vs. children

 Neonates

77 (29.5)

36 (44.4)

0.015

1.96 (0.91–4.23)

0.087

 Children

184 (70.5)

45 (55.6)

 

1 (reference)

 

Initiation of antifungal agents within 24 h

100 (38.3)

41 (50.6)

0.054

1.58 (0.79–3.16)

0.540

Breakthrough invasive candidiasis

24 (9.2)

17 (21.0)

0.010

2.99 (1.04–8.67)

0.043

Septic shock at onset

34 (13.0)

55 (67.9)

<  0.001

16.01 (7.64–33.56)

<  0.001

Underlying renal failure with/without hemodialysis

20 (7.7)

19 (23.5)

<  0.001

5.38 (1.99–14.57)

0.001

Delayed catheter removal > 3 days after illness onset

154 (59.0)

71 (87.7)

<  0.001

6.78 (2.48–18.52)

<  0.001

Treatment regimens

  

0.001

  

 Fluconazole

109 (40.6)

22 (27.2)

 

1 (reference)

 

 Amphotericin B

73 (28.0)

24 (29.6)

 

1.53 (0.70–3.33)

0.289

 Echinocandin

73 (28.0)

23 (28.4)

 

1.04 (0.47–2.31)

0.933

 Combination therapy

6 (2.3)

2 (2.5)

 

1.76 (0.25–12.3)

0.570

 No antifungal treatment

0 (0)

10 (12.3)

 

10.07 (1.6–64.7)

<  0.001

Pathogens

  

0.729

  

 Candida albicans

121 (46.4)

34 (42.0)

   

 Candida parapsilosis

71 (27.2)

24 (58.0)

   

 Candida tropicalis

15 (5.7)

7 (8.6)

   

 Candida glabrata

17 (6.5)

4 (4.9)

   

 Other Candida spp.

36 (13.8)

12 (14.8)

   

Infectious source

  

0.358

  

 Primary bloodstream infection

169 (64.8)

59 (72.8)

   

 Catheter-related bloodstream infection

59 (22.6)

10 (12.3)

   

 Intra-abdominal

22 (8.4)

9 (11.1)

   

 Urological

4 (1.5)

1 (1.2)

   

 Lung

3 (1.1)

1 (1.2)

   

 Meningitis

4 (1.5)

1 (1.2)

  Â